UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

The New England journal of medicine, 2015-09, Vol.373 (13), p.1207-1219

2015

Volltextzugriff (PDF)

Relocalization of DNA lesions to the nuclear pore complex

FEMS yeast research, 2016-12, Vol.16 (8), p.fow095

2016

Volltextzugriff (PDF)

Srs2 and Mus81-Mms4 Prevent Accumulation of Toxic Inter-Homolog Recombination Intermediates

PLoS genetics, 2016-07, Vol.12 (7), p.e1006136-e1006136

2016

Volltextzugriff (PDF)

Replication stress as a source of telomere recombination during replicative senescence in Saccharomyces cerevisiae

FEMS yeast research, 2016-11, Vol.16 (7), p.fow085

2016

Volltextzugriff (PDF)

The Shu complex is a conserved regulator of homologous recombination

FEMS yeast research, 2016-09, Vol.16 (6), p.fow073

2016

Volltextzugriff (PDF)

Decrease in nickel sensitization in a Danish schoolgirl population with ears pierced after implementation of a nickel-exposure regulation

British journal of dermatology (1951), 2002-04, Vol.146 (4), p.636-642

2002

Volltextzugriff (PDF)

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-10, Vol.375 (14), p.1319-1331

2016

Volltextzugriff (PDF)

Transcriptional regulation of tumor necrosis factor-α in keratinocytes mediated by interleukin-1β and tumor necrosis factor-α

Experimental dermatology, 2002-12, Vol.11 (6), p.592-598

2002

Volltextzugriff (PDF)

The nucleolytic resolution of recombination intermediates in yeast mitotic cells

FEMS yeast research, 2016-09, Vol.16 (6), p.fow065

2016

Volltextzugriff (PDF)

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

The Lancet (British edition), 2016-04, Vol.387 (10027), p.1551-1560

2016

Volltextzugriff (PDF)

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

Blood, 2011-11, Vol.118 (19), p.5126-5129

2011

Volltextzugriff (PDF)

74P Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)

Annals of oncology, 2020-12, Vol.31, p.S1448-S1448

2020

Volltextzugriff (PDF)

75P Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)

Annals of oncology, 2020-12, Vol.31, p.S1448-S1448

2020

Volltextzugriff (PDF)

Nickel‐induced proliferation of both memory and naive T cells in patch test‐negative individuals

Clinical and experimental immunology, 1999-08, Vol.117 (2), p.217-222

1999

Volltextzugriff (PDF)

Association of TNFA gene polymorphism at position -308 with susceptibility to irritant contact dermatitis

Immunogenetics (New York), 2000-03, Vol.51 (3), p.201-205

2000

Volltextzugriff (PDF)

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

Blood, 2007-06, Vol.109 (11), p.4655-4662

2007

Volltextzugriff (PDF)

A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors

Annals of oncology, 2017-09, Vol.28, p.v420-v420

2017

Volltextzugriff (PDF)

A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors

Annals of oncology, 2017-09, Vol.28, p.v408-v408

2017

Volltextzugriff (PDF)

Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia

Leukemia & lymphoma, 2016-09, Vol.57 (9), p.2037-2046

2016

Volltextzugriff (PDF)

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-10, Vol.375 (14), p.1319-1331

2016

Volltextzugriff (PDF)

Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients

British journal of haematology, 2015-07, Vol.170 (1), p.40-49

2015

Volltextzugriff (PDF)

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

Haematologica (Roma), 2015-08, Vol.100 (8), p.e311

2015

Volltextzugriff (PDF)

A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

Annals of oncology, 2017-09, Vol.28, p.v330-v331

2017

Volltextzugriff (PDF)

Intercellular adhesion molecule-I (ICAM-I) expression correlated to inflammation

British journal of dermatology (1951), 1989-04, Vol.120 (4), p.479-484

1989

Volltextzugriff (PDF)

1 – 25 von 542

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(485)
Mit Volltextzugriff
(452)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(325)
Life Sciences & Biomedicine
(293)
Humans
(198)
Female
(82)
Biological And Medical Sciences
(80)
Male
(73)
Adult
(71)
Medical Sciences
(61)
Saccharomyces Cerevisiae - Genetics
(60)
Biochemistry & Molecular Biology
(59)
Middle Aged
(58)
Dna Damage
(50)
Microbiology
(46)
Dna Repair
(44)
Aged
(43)
Cell Biology
(43)
Saccharomyces Cerevisiae
(42)
Saccharomyces Cerevisiae Proteins - Metabolism
(41)
Infectious Diseases
(38)
Saccharomyces Cerevisiae - Metabolism
(38)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Relocalization of DNA lesions to the nuclear pore complex

Srs2 and Mus81-Mms4 Prevent Accumulation of Toxic Inter-Homolog Recombination Intermediates

Replication stress as a source of telomere recombination during replicative senescence in Saccharomyces cerevisiae

The Shu complex is a conserved regulator of homologous recombination

Decrease in nickel sensitization in a Danish schoolgirl population with ears pierced after implementation of a nickel-exposure regulation

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Transcriptional regulation of tumor necrosis factor-α in keratinocytes mediated by interleukin-1β and tumor necrosis factor-α

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

The nucleolytic resolution of recombination intermediates in yeast mitotic cells

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

74P Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)

75P Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)

Nickel‐induced proliferation of both memory and naive T cells in patch test‐negative individuals

Association of TNFA gene polymorphism at position -308 with susceptibility to irritant contact dermatitis

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors

A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors

Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

Intercellular adhesion molecule-I (ICAM-I) expression correlated to inflammation

Suchergebnisse filtern